Clinical trials: Controlled Hypertension
Persistent Pulmonary Hypertension of the Newborn
Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
This study assessed the safety and treatment effect of intravenous (IV) Remodulin as an add-on therapy in neonates with persistent pulmonary hypertension of the newborn (PPHN).
- Trial name
- NCT02261883
- Testing
- IV Remodulin
- Where
- 14 sites in United States
- Volunteers
- 42 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension
This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension
- Trial name
- NCT00477269
- Testing
- Imatinib mesylate
- Where
- 13 sites in United States, Austria and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-3 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.
- Trial name
- NCT05199129
- Testing
- HCP1904-3, RLD2001-1
- Where
- South Korea
- Volunteers
- 166 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Glaucoma, Neovascular
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.
- Trial name
- VEGA (NCT02396316)
- Testing
- Aflibercept (Eylea, BAY 86-5321)
- Where
- 19 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
- Trial name
- NCT05147805
- Testing
- Treprostinil Palmitil
- Where
- 92 sites in United States, Argentina and 15 more
- Volunteers
- 102 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with…
- Trial name
- UNISUS (NCT04273945)
- Testing
- Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg
- Where
- 274 sites in United States, Argentina and 40 more
- Volunteers
- 935 people
- Sponsor
- Actelion
Open Angle Glaucoma
A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma
The purpose of this study is to demonstrate the safety and tolerability of ONL1204 Ophthalmic Solution in patients with progressing open angle glaucoma.
- Trial name
- NCT05160805
- Testing
- ONL1204 Ophthalmic solution (Dose A), ONL1204 Ophthalmic solution (Dose B)
- Where
- 11 sites in Australia, New Zealand
- Volunteers
- 25 people
- Sponsor
- ONL Therapeutics
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
- Trial name
- NCT02674854
- Testing
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Aerie Pharmaceuticals
Chronic Liver Disease
VIATORR Device Registry
The primary objective is to confirm the clinical performance and safety of the GORE® VIATORR® TIPS (Transjugular Intrahepatic Portosystemic Shunt) Endoprosthesis with Controlled Expansion throughout the device functional lifetime…
- Trial name
- NCT05661331
- Testing
- Transjugular intrahepatic portosystemic shunt
- Where
- 7 sites in Austria, France and 3 more
- Volunteers
- 196 people
- Sponsor
- W.L.Gore & Associates
Pulmonary Hypertension
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
The purpose of this multi-center international trial is to evaluate the safety and effectiveness of adding iloprost or placebo (an inactive substance that contains no active study drug) to sildenafil therapy for pulmonary…
- Trial name
- VISION (NCT00302211)
- Testing
- Inhaled Iloprost (5 μg), Sildenafil, Bosentan
- Volunteers
- 67 people
- Sponsor
- Actelion
Refractory Hypertension or Drug-intolerant Hypertension
Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN
Prospective, multicenter, randomized, controlled, blinded, and superiority - designed; The target population undergoes a screening treatment with prescribed medications for at least 4 weeks.
- Trial name
- ModulationHTN2 (NCT06877221)
- Testing
- ultrasound renal denervation
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Shenzhen Pulsecare Medical Technology Co., Ltd.
Primary Open Angle Glaucoma, Open Angle Glaucoma
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
The goal of this clinical trial is to show non-inferiority of the MIMS® device/procedure with Mitomycin-C, in terms of its surgical success rate, compared to trabeculectomy with Mitomycin-C in subjects diagnosed with primary open…
- Trial name
- NCT06313749
- Testing
- Minimally Invasive Micro Sclerostomy Device
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Sanoculis Ltd
Hypertension
Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
The purpose of this study is to gain an understanding of the actual use of candesartan cilexetil (Blopress) in patients with hypertension, and to examine the changes in parameters such as blood pressure.
- Trial name
- NCT02211638
- Testing
- Candesartan Cilexetil
- Where
- Japan
- Volunteers
- 18,113 people
- Sponsor
- Takeda
Renal Artery Obstruction, Hypertension, Renovascular
Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery
This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV elamipretide for reduction of reperfusion injury…
- Conditions
- Renal Artery Obstruction, Hypertension, Renovascular, Ischemia Reperfusion Injury
- Trial name
- EVOLVE (NCT01755858)
- Testing
- Bendavia
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Stealth BioTherapeutics Inc.
Pulmonary Hypertension
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study was an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who were currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- NCT00325442
- Testing
- Oral treprostinil (UT-15C) sustained release tablets
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 354 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Familial Persistent, of the Newborn
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.
- Trial name
- NCT01720524
- Testing
- iv sildenafil
- Where
- 42 sites in United States, Belgium and 10 more
- Volunteers
- 59 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Erectile Dysfunction
Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction and Hypertension
The purpose of this study is to evaluate the efficacy and safety of SK3530 in men with ED and hypertension who were taking antihypertensive medication.
- Trial name
- NCT00644007
- Testing
- SK3530
- Where
- South Korea
- Volunteers
- 109 people
- Sponsor
- SK Chemicals Co., Ltd.
Hypertension
Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects
This was a 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group study to determine the antihypertensive dose range, efficacy, safety and tolerability of TOPROL-XL ® (metoprolol succinate)…
- Trial name
- 307A (NCT00255528)
- Testing
- metoprolol succinate
- Where
- 31 sites in United States, Dominican Republic
- Volunteers
- 144 people
- Sponsor
- AstraZeneca
Pre-hypertension, Cardiovascular Diseases
Watermelon Dose Response Blood Pressure Study
1. Primary outcome: To evaluate the dose response effects of watermelon flesh in regulating Blood Pressure (BP) in individuals with pre-hypertension. 2.
- Trial name
- WMBP (NCT05892328)
- Testing
- Watermelon Flesh Dose 1, Watermelon Flesh Dose 2, Control
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Hypertension
Hyzaar Asia HEAALTH (0954A-950)
The objective of the study is to estimate the percentage of patients who reach blood pressure goal after 8 weeks of treatment with losartan/HCTZ combination.
- Trial name
- NCT00354991
- Testing
- losartan potassium (+) hydrochlorothiazide
- Volunteers
- 437 people
- Sponsor
- Merck Sharp & Dohme LLC